Patents by Inventor Yexin LIAO

Yexin LIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compound as ACC inhibitor and use thereof
    Patent number: 11186587
    Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 30, 2021
    Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong Wang, Liwen Zhao, Yazhou Wang, Xu Quan, Chunhuan Jiang, Hongyan Chen, Menghua Chen, Chao Li, Yexin Liao, Qi Liu, Chen Wang, Hai Wang, Shengwei Yang, Guochuang Zheng
  • COMPOUND AS ACC INHIBITOR AND USE THEREOF
    Publication number: 20200165265
    Abstract: Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.
    Type: Application
    Filed: July 25, 2018
    Publication date: May 28, 2020
    Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.
    Inventors: Yong WANG, Liwen ZHAO, Yazhou WANG, Xu QUAN, Chunhuan JIANG, Hongyan CHEN, Menghua CHEN, Chao LI, Yexin LIAO, Qi LIU, Chen WANG, Hai WANG, Shengwei YANG, Guochuang ZHENG